RxDoctor Payments DataLook up a doctor →

David Bruce, DO

Family Medicine · Mesa, AZNPI 1740250505

Payments from drug & device makers

$72,035in general payments, 2019–2025

Across 444 payments — averaging $162.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$65K
  • AstraZeneca$1K
  • Novo Nordisk$879
  • GSK$764
  • Lilly USA, LLC$508
  • Boehringer Ingelheim$500
  • plus $4K from 37 others

What the payments were for

  • Food & beverage$7,257100%
  • Education$60%
  • Entertainment$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$72,035 in reported general payments places this provider in the 95th percentile of 2,099 family medicine providers in Arizona.

See all family medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$21,329
Medicare patients
120
Services billed
207

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin21$27,459
ProliaDenosumab12$19,103
TrulicityDulaglutide11$17,973
OzempicSemaglutide13$17,838
EliquisApixaban15$13,730
XareltoRivaroxaban14$12,926
Soliqua 100-33Insulin Glargine/Lixisenatide11$5,795
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$2,159
Atorvastatin Calcium205$2,072
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$2,051
Gabapentin94$1,885
Tamsulosin Hcl72$1,637
Duloxetine Hcl53$1,431
Rosuvastatin Calcium130$1,363
Pantoprazole Sodium88$1,251

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$500$27,45921 claims
AmgenProlia$285$19,10312 claims
Lilly USA, LLCTrulicity$508$17,97311 claims
Novo NordiskOzempic$879$17,83813 claims
PfizerEliquis$110$13,73015 claims
Johnson & JohnsonXarelto$318$12,92614 claims
Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus$185$7,03322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,099 family medicine providers in Arizona.

Other family medicine in Mesa

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →